Search research articles
Contact Us
Filters
Showing results (41-50 of 357) with videos related to
Page
of 36
Sort By:
Alimentary Pharmacology & Therapeutics
|
March 21, 2021
Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply
Vipul Jairath, Ahmed Almradi, Rish K Pai, et al.
Intestinal Research
|
May 11, 2018
The old versus the new: which do you keep in postoperative Crohn's disease?
Paulo Gustavo Kotze, Christopher Ma, Miguel Regueiro, et al.
Therapeutic Advances in Gastroenterology
|
June 7, 2023
A review of the role of intermittent fasting in the management of inflammatory bowel disease
Celeste M Lavallee, Andreina Bruno, Christopher Ma, et al.
Nutrients
|
November 11, 2022
The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review
Celeste M Lavallee, Andreina Bruno, Christopher Ma, et al.
Expert Opinion on Investigational Drugs
|
July 31, 2018
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease
Christopher Ma, Vipul Jairath, Reena Khanna, et al.
Journal of Inflammation Research
|
February 16, 2018
Clinical utility of ustekinumab in Crohn's disease
Paulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi, et al.
Gastroenterology & Hepatology
|
May 4, 2022
Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease
Rocio Sedano, Christopher Ma, Vipul Jairath, et al.
Journal of the American Chemical Society
|
October 10, 2017
Designer α1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-Glycoproteins
Chao Li, Shilei Zhu, Christopher Ma, et al.
BMC Genomics
|
September 3, 2015
An unsupervised learning approach to find ovarian cancer genes through integration of biological data
Christopher Ma, Yixin Chen, Dawn Wilkins, et al.
Current Drug Targets
|
May 23, 2019
Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?
Hang Hock Shim, Christopher Ma, Paulo Gustavo Kotze, et al.
Page
of 36
Search research articles
Search
Showing results (41-50 of 357) with videos related to
Sort By:
Page
of 36
Alimentary Pharmacology & Therapeutics
|
March 21, 2021
Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials-a missing link. Authors' reply
Vipul Jairath, Ahmed Almradi, Rish K Pai, et al.
Intestinal Research
|
May 11, 2018
The old versus the new: which do you keep in postoperative Crohn's disease?
Paulo Gustavo Kotze, Christopher Ma, Miguel Regueiro, et al.
Therapeutic Advances in Gastroenterology
|
June 7, 2023
A review of the role of intermittent fasting in the management of inflammatory bowel disease
Celeste M Lavallee, Andreina Bruno, Christopher Ma, et al.
Nutrients
|
November 11, 2022
The Role of Intermittent Fasting in the Management of Nonalcoholic Fatty Liver Disease: A Narrative Review
Celeste M Lavallee, Andreina Bruno, Christopher Ma, et al.
Expert Opinion on Investigational Drugs
|
July 31, 2018
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease
Christopher Ma, Vipul Jairath, Reena Khanna, et al.
Journal of Inflammation Research
|
February 16, 2018
Clinical utility of ustekinumab in Crohn's disease
Paulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi, et al.
Gastroenterology & Hepatology
|
May 4, 2022
Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel Disease
Rocio Sedano, Christopher Ma, Vipul Jairath, et al.
Journal of the American Chemical Society
|
October 10, 2017
Designer α1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-Glycoproteins
Chao Li, Shilei Zhu, Christopher Ma, et al.
BMC Genomics
|
September 3, 2015
An unsupervised learning approach to find ovarian cancer genes through integration of biological data
Christopher Ma, Yixin Chen, Dawn Wilkins, et al.
Current Drug Targets
|
May 23, 2019
Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?
Hang Hock Shim, Christopher Ma, Paulo Gustavo Kotze, et al.
Page
of 36